Core Viewpoint - Tianjing Bio (IMAB) has shown significant stock price movement and financial performance, indicating potential growth in the biopharmaceutical sector focused on innovative therapies for cancer and autoimmune diseases [1][2]. Financial Performance - As of December 31, 2023, Tianjing Bio reported total revenue of 27.644 million RMB, representing a year-on-year increase of 112.48% [1]. - The company recorded a net profit attributable to shareholders of -1.466 billion RMB, which is a 41.54% increase compared to the previous year [1]. Upcoming Events - Tianjing Bio is scheduled to disclose its fiscal year 2024 mid-term report on August 28, 2023, before the market opens in the Eastern US [2]. Company Overview - Tianjing Bio is an offshore holding company that operates through its domestic subsidiary, focusing on innovative biopharmaceuticals in the fields of tumor immunology and autoimmune diseases [2]. - The company's mission is to develop groundbreaking innovative biopharmaceuticals that address unmet clinical needs and improve the quality of life for patients globally [2].

Core Viewpoint - Everest Medicines has made a strategic equity investment of US$30.9 million in I-Mab, acquiring a 16.1% ownership stake, which aligns with its focus on next-generation oncology programs and enhances its presence in the U.S. market [1][4]. Investment Details - The investment will be made through the subscription of 15,846,154 American Depositary Shares (ADSs) at an offering price of $1.95 per ADS, contributing to total gross proceeds of approximately US$65 million for I-Mab [5]. - Following the investment, Everest will hold a total of 15,846,154 ADSs and 6,078,571 ordinary shares of I-Mab, representing approximately 16.1% of I-Mab's total issued share capital [5]. Clinical Development Synergies - I-Mab's bispecific antibody pipeline, particularly the 4-1BB receptor targeting platform, is complementary to Everest's existing mRNA cancer vaccines and in vivo CAR-T platform, potentially accelerating the development of pipeline products for both companies [2][3]. - The collaboration may leverage I-Mab's clinical translational capabilities in the U.S. and Everest's clinical capabilities in Asia, enhancing the global expansion of their respective product pipelines [3][4]. Product Pipeline - I-Mab's key pipeline products include Givastomig (Claudin 18.2 x 4-1BB bispecific antibody), which has shown an overall response rate (ORR) of 83% in a Phase 1b trial for first-line gastric cancers [1][9][13]. - Other notable candidates in I-Mab's pipeline include Ragistomig (PD-L1 x 4-1BB bispecific antibody) and Uliledlimab (CD73 antibody), indicating a strong focus on precision immuno-oncology agents [8][13]. Company Background - Everest Medicines is a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapeutics, particularly in oncology, renal diseases, infectious diseases, and autoimmune disorders [11]. - I-Mab is a U.S.-based global biotech company focused on precision immuno-oncology, with a differentiated pipeline aimed at treating various cancers [8][13].

Group 1 - Company Gindalbie Metals announced the acquisition of 15.84 million American Depositary Shares (ADS) of I-Mab at a price of $1.95 per ADS, totaling approximately $30.9 million [1] - Following the acquisition, the company will hold a total of 15.84 million ADS and 6.08 million ordinary shares, representing about 16.1% of I-Mab's total issued share capital post-transaction [1] - The company focuses on innovative drug and vaccine research and development, with a strategic pipeline of promising clinical-stage products aimed at addressing unmet medical needs globally [1] Group 2 - I-Mab is a global biotechnology company headquartered in the United States, specializing in precision immuno-oncology drugs for cancer treatment [2] - I-Mab has three clinical-stage pipeline products, including Givastomig, Ragistomig, and Uliledlimab, which are designed to target specific cancer markers [2] - The board believes that the acquisition will enhance I-Mab's unique capabilities in clinical translation, particularly in the U.S., and complement the company's existing investments in mRNA cancer vaccines [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴該 等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號：1952） Everest Medicines Limited 雲 頂 新 耀 有 限 公 司 自願性公告 本公告由雲頂新耀有限公司（「本公司」）自願作出。 本 公 司 董 事（「 董 事 」）會（「 董 事 會 」）宣 佈 ， 於 2025 年 8 月 1 日 ， 本 公 司 認 購 I -Mab （「 I -M a b 」）（ 一 間 於 納 斯 達 克 全 球 市 場 上 市 之 公 司 ， 股 份 代 號 為「 IM AB 」）之 15,846,154股美國預託股份（「ADS」）（ 每十(10)股ADS相當於二十三(23)股普通股 ） （「認購事項」），每股ADS為1.95美元（ 相當於約每股ADS 15.3港元 ）。認購事項之 總代價為30.9百萬美元（ 相當於約242.6百萬港元 ）。認購事項完成後，本公司將合 共持有15,846,154股ADS ...

Core Viewpoint - I-Mab has announced a public offering of American Depositary Shares (ADSs) to raise approximately $65 million for clinical development and general corporate purposes [1][3]. Group 1: Offering Details - The offering consists of 33,333,334 ADSs, priced at $1.95 per ADS, representing a total of 76,666,668 ordinary shares [1]. - The offering is expected to close on August 5, 2025, subject to customary closing conditions [1]. - Participation in the offering includes both new and existing investors such as Everest Medicines and Janus Henderson Investors [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to fund ongoing clinical development of pipeline product candidates, including a Phase 2 trial of givastomig [3]. - Givastomig is a bispecific antibody targeting Claudin 18.2, aimed at generating clinically meaningful progression-free survival data by the end of 2027 [3]. Group 3: Company Overview - I-Mab is a U.S.-based global biotech company focused on precision immuno-oncology agents for cancer treatment [6]. - The company's lead product, givastomig, is designed to treat Claudin 18.2-positive gastric cancers and is currently in Phase 1 trials [6].

Market Capitalization Overview - New Oriental has a market capitalization of 15.747 billion [2] - TAL Education (好未来) has a market capitalization of 11.040 billion [2] - Vipshop (唯品会) has a market capitalization of 9.610 billion [2] - Miniso (名创优品) has a market capitalization of 5.940 billion [2] - Zai Lab (再鼎医药) has a market capitalization of 4.200 billion [2] - Huya (虎牙) has a market capitalization of 7.500 billion [2] Stock Performance - New Oriental's stock increased by 0.36 (+8.09%) [2] - TAL Education's stock decreased by 0.27 (-0.60%) [2] - Vipshop's stock increased by 0.56 (+2.49%) [2] - Miniso's stock increased by 0.01 (+0.07%) [2] - Zai Lab's stock decreased by 0.81 (-4.06%) [2] - Huya's stock increased by 0.03 (+0.75%) [2] Additional Company Insights - Financial One Account (金融壹账通) has a market capitalization of 2.91 million [3] - Xunlei (迅雷) has a market capitalization of 4.48 million [3] - Huami Technology (华米科技) has a market capitalization of 1.64 million [3] - Tuniu (途牛) has a market capitalization of 1.21 million [3] - Aiqiyi (爱奇艺) has a market capitalization of 24.11 billion [2]

Core Insights - Tianjing Bio (IMAB) opened with a significant increase of 19.41% on July 31, reaching a price of $2.03 per share, with a trading volume of $3.75 million and a total market capitalization of $166 million [1] - As of December 31, 2023, Tianjing Bio reported total revenue of 27.644 million RMB, representing a year-on-year growth of 112.48%, while the net profit attributable to shareholders was -1.466 billion RMB, showing a year-on-year increase of 41.54% [1] Company Overview - Tianjing Bio is an offshore holding company registered abroad, operating through its domestic subsidiary Tianjing Bio, focusing on innovative biopharmaceuticals in the fields of tumor immunology and autoimmune diseases [2] - The company aims to develop innovative biopharmaceuticals with "first-in-class" and "best-in-class" potential globally, addressing unmet clinical needs and improving the quality of life for patients worldwide [2] - Tianjing Bio is striving to become a leading biopharmaceutical company rooted in China and oriented towards global markets [2]

Group 1 - The top five gainers among Chinese concept stocks include 707 Cayman Holdings with a rise of 41.31%, ATA Creativity Global increasing by 33.36%, and RCON (研控科技) up by 20.35% [1] - 707 Cayman Holdings closed at a price of 5.935, with a gain of 1.735 and a trading volume of 2.7565 million [1] - ATA Creativity Global's latest price is 1.700, showing an increase of 0.425 and a trading volume of 0.8189 million [1] Group 2 - RCON (研控科技) reached a price of 2.720, with a rise of 0.460 and a trading volume of 20.0451 million [1] - 康乃德生物 (CNTB) closed at 2.100, reflecting a gain of 0.350 and a trading volume of 0.5651 million [1] - I-Mab (IMAB) saw its price at 2.030, with an increase of 0.330 and a trading volume of 3.7652 million [1]

Market Capitalization Summary - New Oriental has a market capitalization of 15.98 billion [2] - MIN (Ming Chao) has a market capitalization of 10.21 billion [2] - TAL has a market capitalization of 9.38 billion [2] - The market capitalization of various companies includes: - 7.77 billion for Grape Fang [2] - 6.21 billion for Yi Pin Hui [2] - 4.28 billion for Zai [2] - 3.83 billion for Huya [2] Stock Performance - New Oriental's stock increased by 0.28 (+1.45%) [2] - MIN's stock decreased by 0.20 (-4.25%) [2] - TAL's stock decreased by 0.15 (-0.69%) [2] - Grape Fang's stock decreased by 2.39 (-5.11%) [2] - Yi Pin Hui's stock increased by 0.38 (+1.94%) [2] - Zai's stock decreased by 0.10 (-0.93%) [2] Additional Company Insights - The market capitalization of various companies shows a diverse range, with some experiencing significant fluctuations in stock prices [2] - Companies like Huami and Cheetah Mobile have market capitalizations of 1.76 billion and 1.73 billion respectively, with varying stock performance [4] - The overall market trends indicate a mix of gains and losses across different sectors, reflecting the volatility in the market [4]

Core Insights - Tianjing Bio (IMAB) experienced a stock price increase of 11.14% on July 30, reaching $1.889 per share, with a total market capitalization of $154 million [1] - The company reported total revenue of 27.644 million RMB for the year ending December 31, 2023, representing a year-on-year growth of 112.48%, while the net profit attributable to shareholders was -1.466 billion RMB, showing a year-on-year increase of 41.54% [1] Company Overview - Tianjing Bio is an offshore holding company that operates through its domestic subsidiary, focusing on innovative biopharmaceuticals in the fields of tumor immunology and autoimmune diseases [2] - The company's mission is to develop groundbreaking innovative biopharmaceuticals that address unmet clinical needs and improve the quality of life for patients globally [2] - Tianjing Bio aims to establish itself as a leading biopharmaceutical company rooted in China and oriented towards global markets [2]